In CMV high-risk kidney transplant recipients (KTR), recommended antiviral human cytomegalovirus (CMV) treatment can lead to nephrotoxicity and antiviral resistance. In this case report, we report the development of a combined CMV-UL97 C592F and CMV UL54 T503I resistance mutation in a high-risk KTR most probably linked to the previous treatment with valganciclovir (valGCV) and ganciclovir (GCV). Routine CMV screening, in addition with testing of CMV immunity and applied stewardship programs for ganciclovir might have been helpful in preventing the development of these mutations in this patient.
aInstitute of Medical Microbiology
bInstitute of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Jena
cInstitute for Virology, Ulm University Hospital, Ulm
dDepartment of Internal Medicine III, Jena University Hospital, Jena, Germany.
Correspondence to Matthias Karrasch, MD, Institute of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany. Tel: +49 3641 9 325073; e-mail: firstname.lastname@example.org
Received 3 May, 2019
Accepted 17 May, 2019